Xichen Lin

Dr. Lin brings close to 20 years of experience in drug discovery and development and has delivered multiple clinical candidates, including several Phase 2 assets. Prior to ShouTi, Dr. Lin worked at Novo Nordisk as Head of Asia Pacific External Innovation, responsible for the identification and evaluation of external opportunities in the region. Given his expertise in small molecules, Dr. Lin also led the formation of a strategic alliance between Novo Nordisk and Evotec focused on small molecule drug discovery and development targeting diabetes and obesity. Dr. Lin started his professional career at GSK as a medicinal chemist and later transferred to Shanghai to build and lead the chemistry team. In this role, he led global drug discovery teams to deliver clinical candidates in various disease areas including COPD, asthma, multiple sclerosis, and Alzheimer’s disease. He ended his GSK tenure as Head of the Global Neuroinflammation Discovery Performance Unit, covering target identification through Phase 2 studies. Dr. Lin holds more than 30 patents and has authored more than 35 publications. He obtained a Ph.D. from The Pennsylvania State University and a B.S. from Peking University.